Form 4: Stoke Therapeutics GC Sells Shares for Tax Obligations

Stoke Therapeutics' General Counsel, Jonathan Allan, sold 1,683 shares of common stock to cover tax withholding liabilities.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a sale of common stock.
• The transaction involved the disposition of 1,683 shares of common stock.
• The shares were sold at a weighted average price of $18.238 per share, with prices ranging from $18.00 to $18.50.
• The sale was an issuer-mandated transaction to satisfy tax withholding liabilities related to the vesting and settlement of restricted stock units.
• Following this transaction, Jonathan Allan directly beneficially owns 23,948 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, issuer-mandated sale for tax purposes related to executive compensation, which is neutral in sentiment. It does not indicate a change in company fundamentals or management's view of the company's prospects.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This filing is a routine insider transaction for tax purposes and does not reflect broader industry trends or competitive positioning. It is a standard disclosure for executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related transaction and not a discretionary sale indicating a change in confidence.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations arising from the vesting of restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, maintaining a 'hold' stance based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Jonathan Allan, Insider Trading, Stock Sale, Form 4, Tax Withholding, Restricted Stock Units, Biotechnology, Pharmaceuticals